CQMedical
The commercial arm of CanaQuest Medical Corp
CanaQuest Medical Corp, a clinical-stage, life sciences company, is focused on the drug discovery and development of next-generation targeted therapeutics within the endocannabinoid system and specific brain receptors.
Mentanine® – as a safer alternative
Pre-clinical trials conducted by neuroscientists at Western University demonstrated: decreased anxiety, depression, PTSD, and decreased inflammation in the brain.
CanaQuest has created a novel master formulation derived from cannabidiol + IP formula. The company has a drug candidate, CQ-001, which is positioned for clinical trials, targeting epilepsy.
A nutraceutical version of the master formulation (less potent, different format) branded as Mentanine®, has been produced for Clinical (human) Studies to obtain Data for various indications, and future Clinical Trials.
Its non-psychoactive properties provide a safe and effective alternative to traditional treatments with minimal effects.
Study Partnership
NHL Alumni Association (NHLAA), NEEKA Health Canada(“NEEKA”),and CanaQuest Medical Corp (“CanaQuest”) are pleased to announce a transformative study partnership that will investigate the efficacy of Mentanine® as a potential treatment to reduce anxiety in former NHL players.
If you have any questions about any of our products, please do reach us.
[email protected]